Literature DB >> 9660364

Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort.

L Mandelbrot1, J Le Chenadec, A Berrebi, A Bongain, J L Bénifla, J F Delfraissy, S Blanche, M J Mayaux.   

Abstract

CONTEXT: It is unclear whether elective cesarean delivery may have a protective effect against the transmission of human immunodeficiency virus 1 (HIV-1).
OBJECTIVE: To investigate whether mode of delivery has an impact on perinatal HIV-1 transmission in the presence of zidovudine prophylaxis.
DESIGN: A prospective cohort study.
SETTING: The 85 perinatal centers in the French Perinatal Cohort, from 1985 to 1996. PATIENTS: A total of 2834 singleton children born to mothers with HIV-1 infection. MAIN OUTCOME MEASURE: Human immunodeficiency virus 1 infection of the infant.
RESULTS: No zidovudine was used in 1917 pregnancies and zidovudine prophylaxis was used in 902 pregnancies. Cesarean deliveries were performed in 10.9% on an emergent basis and in 8.3% electively, prior to labor or membrane rupture. In 1917 mothers who did not receive zidovudine, of 1877 with information on mode of delivery, 17.2% transmitted HIV-1 to their child. Risk factors statistically significantly associated with transmission were maternal p24 antigenemia, cervicovaginal infections during pregnancy, amniotic fluid color, and rupture of membranes 4 hours or more before delivery. Mode of delivery was not related to transmission. In 902 mothers receiving zidovudine, transmission was 6.4% in 872 with information on mode of delivery, and elective cesarean delivery (n = 133) was associated with a lower transmission rate than emergent cesarean or vaginal delivery (0.8%, 11.4%, and 6.6%, respectively; P=.002). In a multivariate analysis of all mother-child pairs, including obstetrical risk factors, maternal p24 antigenemia, and zidovudine prophylaxis, interaction between mode of delivery and zidovudine prophylaxis was significant (P=.007). In the multivariate analysis of pregnancies with zidovudine prophylaxis, factors related to transmission rate were maternal p24 antigenemia, amniotic fluid color, and mode of delivery. Adjusted odds ratios (95% confidence intervals) were 1.6 (0.7-3.6) for emergent cesarean delivery and 0.2 (0.0-0.9) for elective cesarean delivery (P = .04) in comparison with vaginal delivery.
CONCLUSIONS: We observed an interaction between zidovudine prophylaxis and elective cesarean delivery in decreasing transmission of HIV-1 from mother to child. This observation may have clinical implications for prevention.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660364     DOI: 10.1001/jama.280.1.55

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  32 in total

1.  Labour care of women with HIV infection. Article did not highlight current guidelines.

Authors:  G P Taylor; E G Lyall; G Tudor-Williams; L Regan; J Smith
Journal:  BMJ       Date:  1999-08-07

Review 2.  Fetal pharmacotherapy.

Authors:  Gideon Koren; Gil Klinger; Arne Ohlsson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Prevention of perinatal HIV transmission: current status and future developments in anti-retroviral therapy.

Authors:  Athena P Kourtis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines).

Authors:  David R Burdge; Deborah M Money; John C Forbes; Sharon L Walmsley; Fiona M Smaill; Marc Boucher; Lindy M Samson; Marc Steben
Journal:  CMAJ       Date:  2003-06-24       Impact factor: 8.262

5.  Decline in mortality in children with HIV in the UK and Ireland: argument is flawed.

Authors:  S W P Mhlongo; P M H Maduna
Journal:  BMJ       Date:  2004-02-28

6.  Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals.

Authors:  Charmaine P Mutucumarana; Joshua Eudailey; Erin P McGuire; Nathan Vandergrift; Gerald Tegha; Charles Chasela; Sascha Ellington; Charles van der Horst; Athena P Kourtis; Sallie R Permar; Genevieve G Fouda
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

Review 7.  Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Authors:  Nila Bhana; Douglas Ormrod; Caroline M Perry; David P Figgitt
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 8.  Advances in prevention of mother-to-child HIV transmission.

Authors:  Chokechai Rongkavilit; Basim I Asmar
Journal:  Indian J Pediatr       Date:  2004-01       Impact factor: 1.967

9.  Cost-effectiveness of Childbirth Strategies for Prevention of Mother-to-child Transmission of HIV Among Mothers Receiving Nevirapine in India.

Authors:  Kanchan Mukherjee
Journal:  Indian J Community Med       Date:  2010-01

10.  Preventing mother-to-child transmission of HIV in resource-limited settings: the Elizabeth Glaser Pediatric AIDS Foundation experience.

Authors:  Allison Spensley; Tabitha Sripipatana; Abigail Norris Turner; Chuck Hoblitzelle; Joanna Robinson; Catherine Wilfert
Journal:  Am J Public Health       Date:  2008-08-13       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.